TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05412368

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups

Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups
Study: NCT04702022

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18FDG PET / CT
Description: The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18FDG PET / CT
Description: The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18FDG PET / CT
Description: The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
Study: NCT04903054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lulizumab
Description: Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin®
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin®
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study: NCT06377670

Intervention type: PROCEDURE
Intervention: Wassel IV Thumb Duplication Surgery
Description: This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
Study: NCT04903054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Standard of Care: Renal transplant rejection prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Standard of Care: Renal transplant rejection prophylaxis.
Study: NCT06458985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosing Recovery: A Decision Aid and Toolkit
Description: The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
Study: NCT04548791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
Study: NCT05145829

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: Sentinel node mapping using MRI
Description: Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
Study: NCT05677542

Intervention type: DRUG
Intervention: secukinumab
Description: all patients who received secukinumab

Intervention type: DRUG
Intervention: secukinumab
Description: all patients who received secukinumab
Study: NCT06224491

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Reflex locomotion according to Vojta
Description: Tactile stimulation according to Vojta´s reflex locomotion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex locomotion according to Vojta
Description: Tactile stimulation according to Vojta´s reflex locomotion
Study: NCT05033821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted FOY+ImPACT
Description: The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
Study: NCT05299905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality using Semi-CAVE
Description: The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality using the HMD
Description: The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
Study: NCT06037486

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucometer Test
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use
Study: NCT04708366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol 400
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Study: NCT06418672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go Sun Smart Georgia (GSSG)
Description: Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go Sun Smart Georgia (GSSG)
Description: Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups.
Study: NCT04863872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proactive Care Management
Description: Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Care Management
Description: Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: my hypo compass education program
Description: Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
Study: NCT06365164

Intervention type: BEHAVIORAL
Intervention: Tactile stimulation
Description: The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
Study: NCT05118698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynostemma
Description: Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynostemma
Description: Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spinach
Description: For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
Study: NCT06109207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 100mg
Description: Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 150mg
Description: Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study: NCT06112366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery of impacted mandibular wisdom teeth (the other side)
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
Study: NCT05849649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BumptUp
Description: The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Brochure
Description: An evidence-based brochure on physical activity
Study: NCT04939805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective CRP apheresis using the PentraSorb®-CRP system
Description: Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
Study: NCT05620849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online program
Description: The online program is 4 weeks and focused on topics such as alcohol and sexual health
Study: NCT05304078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Assessment and Skill-Building Kit (TASK III) Group
Description: The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support and Referral (ISR) Group
Description: The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
Study: NCT05926687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Communication
Description: Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Communication
Description: Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Communication
Description: Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Communication
Description: Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disruptive Behavior
Description: Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disruptive Behavior
Description: Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disruptive Behavior
Description: Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disruptive Behavior
Description: Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Communication + Reduce Frequency
Description: Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour once/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Communication + Add Tools
Description: Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disruptive Behavior + Reduce Frequency
Description: Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour every other week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disruptive Behavior + Add Tools
Description: Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
Study: NCT05588622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
Study: NCT05714176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate Liposomal
Description: 30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: 30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Dextran Injection
Description: 30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
Study: NCT06088017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391(2)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391(2)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-331, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-331, D337
Description: QD, PO